Safety and Efficacy of BAY 2927088 in Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study

Dr. Eric Singhi presents preliminary findings from the Phase I/II SOHO-01 trial, demonstrating that the oral HER2-targeted tyrosine kinase inhibitor BAY 2927088 achieves high response rates and durable disease control in patients with pretreated HER2-mutant NSCLC, with a manageable safety profile.